SCHEMBL2875339

SCHEMBL2875339

COc1cc(CNC(=O)C=Cc2ccccc2)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.64
APP P05067 1/20 0.64
MMP1 P03956 3/20 0.60
MMP2 P08253 3/20 0.60
MMP9 P14780 3/20 0.60
TYR P14679 2/20 0.59
ACHE P22303 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2875338 1.00 MAPT (0.64) MAPTAPPMMP1MMP2MMP9
SCHEMBL802713 0.90 ABCB1 (0.65) MMP9TYRACHE
SCHEMBL1916293 0.90 TYR (0.73) MAPTAPPMMP9TYRACHE
SCHEMBL12299018 0.90 TYR (0.73) MAPTAPPMMP9TYRACHE
SCHEMBL2847211 0.89 TYR (0.61) MMP9TYRACHE
SCHEMBL2853922 0.89 MAPT (0.65) MAPTMMP9TYRACHE
SCHEMBL2847215 0.89 TYR (0.61) MMP9TYRACHE
SCHEMBL2853919 0.89 MAPT (0.65) MAPTMMP9TYRACHE
SCHEMBL7523933 0.88 TYR (0.71) MAPTAPPMMP1MMP2MMP9
SCHEMBL7523925 0.88 TYR (0.71) MAPTAPPMMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778622-B1 PARA-ALKYL-SUBSTITUTED N-(4-HYDROXY-3-METHOXY-BENZYL) CINNAMAMIDES AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2010-01-13 EP claimed
US-7541495-B2 para-alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof GRUENENTHAL GMBH (DE) 2009-06-02 US claimed
US-20070208083-A1 Alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof GRUENENTHAL GMBH (DE) 2007-09-06 US claimed
US-7541495-B2 para-alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof GRUENENTHAL GMBH (DE) 2009-06-02 US disclosed
US-7541495-B2 para-alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof GRUENENTHAL GMBH (DE) 2009-06-02 US disclosed
US-20070208083-A1 Alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof GRUENENTHAL GMBH (DE) 2007-09-06 US disclosed
US-20070208083-A1 Alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof GRUENENTHAL GMBH (DE) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208083-A1 Alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof CES2, GAA, EGLN3 MAPT 2566/4885APP 1168/4885MMP1 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.